Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04540354
Other study ID # LHI-2020-02
Secondary ID 847999
Status Withdrawn
Phase N/A
First received
Last updated
Start date February 1, 2021
Est. completion date January 31, 2023

Study information

Verified date September 2020
Source Leipzig Heart Institute GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to demonstrate that in post-MI patients with symptomatic heart failure who receive optimal medical therapy for this condition, and with reduced LVEF ≤ 35% but low risk for SCD according to a personalised risk score, optimal medical therapy without ICD implantation (index group) is not inferior to optimal medical therapy with ICD implantation (control group) with respect to all-cause mortality.


Description:

Sudden cardiac death (SCD) is a major public health problem, causing ~50% of cardiac fatalities and accounting for ~20% of all deaths in Europe. The majority of SCD cases are associated with coronary artery disease, mostly as a result of ventricular tachyarrhythmias (ventricular tachycardia and ventricular fibrillation) after previous myocardial infarction (MI). A predictor for increased risk of SCD after MI is a severely impaired heart function as expressed by a reduced left ventricular ejection fraction (LVEF). Based on this and on historical multi-national landmark trials, which found improved survival in patients with severely reduced LVEF who received an ICD, current clinical guidelines recommend prophylactic ICD implantation in post-MI patients with a LVEF ≤35% to improve overall survival by prevention of SCD. Current practice of ICD implantation based solely on LVEF has significant limitations and results in substantial over- and undertreatment of patients. Furthermore, current clinical practice is substantially limited by the fact that it is based on out-dated evidence, a point already highlighted in the last version of the ESC guidelines for prevention of SCD. Indeed, since then, mortality and specifically SCD following MI has dramatically decreased. As a result, the risk for SCD has decreased significantly in the last decades rendering questionable whether the clinical benefits attributed to ICD implantation may not be much lower nowadays than that observed in the pivotal trials conducted 15-20 years ago. Due to the inherent risks and considerable costs of the ICD, detailed evaluation of the patient's risks and benefits of ICD implantation is required on a case-by-case basis - leading to a personalised rather than a "one-size-fits-all" treatment approach. To do so, identification of low-risk patients who would not benefit from ICD implantation in parallel with identification of post-MI patients who are at true high risk of SCD regardless of LVEF status is urgently needed. Thus, in sum-mary there is a compelling clinical need to identify patients at high individual risk for SCD in order to protect them effectively with ICD implantation but at the same time refrain from ICD implantation in patients with low individual risk for SCD. The objective of the study is to demonstrate that in post-MI patients with symptomatic heart failure who receive optimal medical therapy for this condition, and with reduced LVEF ≤ 35% but low risk for SCD according to a personalised risk score, optimal medical therapy without ICD implantation (index group) is not inferior to optimal medical therapy with ICD implantation (control group) with respect to all-cause mortality. PROFID-Reduced is a non-commercial, investigator-driven, prospective, parallel-group, randomised, open-label, blinded outcome assessment (PROBE), multi-centre, non-inferiority trial without dedicated investigational medical device (Proof of Strategy Trial) with two groups with 1:1 randomi-sation. It will be conducted in about 12 European countries with more than 150 clinical sites participating The study is event driven and the number of randomised patients is estimated to be 2,480, required to collect 374 first primary outcome events within 30 months of mean follow-up. Total study duration: Enrolment of 30 months. All patients will be followed until 374 valid primary endpoints are reached (event-driven trial) which is expected about 15 months after last patient in. Total study duration of 47 months is expected which might be adapted based on a blinded interim analysis of the overall occurrence of the primary endpoint. Individual study duration: Expected median follow-up time will be about 30 months per patient with a minimum follow-up time of 15 months and a maximum follow-up time of presumably 45 months.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 31, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years. - Documented history of myocardial infarction either as ST segment elevation myocardial infarction (STEMI) or as non-ST segment elevation myocardial infarction (NSTEMI). - Symptomatic heart failure with NYHA class II or III. - On Optimal Medical Therapy (OMT) for at least 3 months prior to enrolment. - LVEF = 35% at transthoracic echocardiography or cardiac magnetic resonance imaging (MRI). - Predicted personalised annual risk of SCD according to the clinical risk calculator =2.5%. - Signed informed consent. Exclusion Criteria: - Class I or IIa indication for implantation of an ICD for secondary prevention of sudden cardiac death and ventricular tachycardia (according to the 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, see Appendix V). - Ventricular tachycardia induced in an electrophysiologic study. - Unexplained syncope when ventricular arrhythmia is suspected as the cause of syncope. - Conclusive clinical indication for CRT (class I or IIa indication according to the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure) - Carrying any implanted cardiac pacemaker, defibrillator or CRT device. - Violation of instruction for use (IFU) of the selected ICD device by at least one of the random group treatments. - Hospitalised with unstable heart failure with NYHA class IV within 1 month prior to enrolment. - Acute coronary syndrome or cardiac revascularization therapy by coronary angioplasty or coronary artery bypass grafting within 3 months prior to enrolment. - Cardiac valve surgery or percutaneous cardiac valvular intervention such as transcatheter aortic valve replacement or transcatheter mitral valve repair performed within 3 months prior to enrolment. - On the waiting list for heart transplantation. - Any known disease that limits life expectancy to less than 1 year. - Participation in another clinical trial, either within the 3 months prior to enrolment or still on-going (participation in sub-studies connected to this trial is permitted). - Previous participation in PROFID-Reduced. - Drug abuse or clinically manifest alcohol abuse.

Study Design


Intervention

Drug:
Optimal Medical Therapy (OMT)
Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
Device:
Implantable cardioverter-defibrillator (ICD)
An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing). The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Leipzig Heart Institute GmbH

Outcome

Type Measure Description Time frame Safety issue
Primary Time from randomisation to the occurrence of all-cause death Randomization to end of study (event-driven, expected about 15 months after last patient in)
Secondary Time from randomisation to death from cardivascular causes Randomization to end of study (event-driven, expected about 15 months after last patient in)
Secondary Time from randomisation to sudden cardiac death Randomization to end of study (event-driven, expected about 15 months after last patient in)
Secondary Time from randomisation to first hospital readmissions for cardiovascular causes after randomisation Randomization to end of study (event-driven, expected about 15 months after last patient in)
Secondary Average length of stay in hospital during the study period Randomization to end of study (event-driven, expected about 15 months after last patient in)
Secondary Quality of life (EQ-5D-5L) trajectories over time At baseline and 6-month intervals thereafter
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy

External Links